# A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria

> **NCT03217591** · PHASE2 · COMPLETED · sponsor: **Akebia Therapeutics** · enrollment: 156 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus With Diabetic Nephropathy

## Interventions

- **DRUG:** IW-1973
- **DRUG:** IW-1973
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03217591
- **Lead sponsor:** Akebia Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-01
- **Primary completion:** 2019-08-20
- **Final completion:** 2019-08-20
- **Target enrollment:** 156 (ACTUAL)
- **Last updated:** 2022-09-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03217591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03217591, "A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03217591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*